I hear you and understand you, bud... I'll be waiting for Jbem's next pick early next week. Sadly, I only participated in a part of the huge run-up in PTBI (long story).
I'm being patient with this one, but if the opportunity cost of staying in is too high, I'll liquidate for a better short-term play. SYN is golden, but it's just unclear when.
We probably don't care about your actuals. After all, you're a legend in your own mind, right?
When you start posting items of value, people will listen. You still haven't answered my question about the MRI data with anything of substance. EOM.
For the time being the PPS has become entirely driven by social media.
That makes getting a true valuation on the company sketchy, at best. For example, no one knows how far Jesi has come in "true" clinical terms.
We need a PR from the company to sustain (or increase) the current PPS.
That's why I keep saying the 5 patient count is arbitrary.
This is not meant to be a statistical study. Just to show safety on a few patients before proceeding with the next larger studies.
You'd think that with 10 centers now that a suitable patient would have been found.
Hate to wish people to get hurt, just to prove a technology works.
We leave that to chance and the man upstairs.
5 patients is an arbitrary number. It's not statistically relevant. 2 patients is also arbitrary.
I think we have seen enough through Jordan and Jesi to "believe" that safety will not be an issue. Thus, I believe that "safety" has now been firmly baked into the PPS.
I know the trial was not designed for anything beyond safety, but after seeing the excellent results with Jordan and Jesi, the market is expecting more. Any signs of improvement or efficacy will either drive the price higher from here, or lower if we don't see any improvement.
Safety is a "done deal," IMHO.